Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.58 |
| ▸ | TEK | Q02763 | 8/20 | 0.58 |
| ▸ | SRC | P12931 | 7/20 | 0.58 |
| ▸ | FLT3 | P36888 | 7/20 | 0.58 |
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | BTK | Q06187 | 4/20 | 0.58 |
| ▸ | FYN | P06241 | 2/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | LTK | P29376 | 1/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.58 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.58 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6460268 | 0.96 | HCK (0.57) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6465423 | 0.87 | SRC (0.59) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6461336 | 0.86 | LCK (0.55) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6463085 | 0.83 | SRC (0.58) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6461510 | 0.82 | HCK (0.54) | LCKTEKSRCFLT3KDR | |
| SCHEMBL2072190 | 0.82 | KDR (0.62) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6468048 | 0.80 | LCK (0.76) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6460206 | 0.76 | LCK (0.61) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6461041 | 0.75 | LCK (1.00) | LCKTEKSRCFLT3KDR | |
| SCHEMBL6465585 | 0.75 | LCK (0.75) | LCKTEKSRCFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | LCK 1/4885TEK 1465/4885SRC 46/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | LCK 6/4885TEK 22/4885SRC 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.